AnaptysBio Inc (nasdaq:ANAB) Share Price

Company Profile

Business description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Contact
10770 Wateridge Circle
Suite 210
San DiegoCA92121
USA
T: +1 858 362-6295
E: [email protected]
https://www.anaptysbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136

Recommended

Our coverage remains overvalued.

Jon Mills, CFA | 14 January 2026

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

William Kerwin, CFA | 12 January 2026

The shares are overvalued as investors are overly excited about defence and gold exposure.

Esther Holloway | 12 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,151.80	24.70	0.27%
CAC 40	8,350.92	3.72	0.04%
DAX 40	25,289.27	131.39	-0.52%
Dow JONES (US)	49,191.99	398.21	-0.80%
FTSE 100	10,169.17	31.82	0.31%
HKSE	26,999.81	391.33	1.47%
NASDAQ	23,709.87	24.03	-0.10%
Nikkei 225	54,341.23	2,401.34	4.62%
NZX 50 Index	13,757.71	101.66	0.74%
S&P 500	6,963.74	0.00	0.00%
S&P/ASX 200	8,820.60	29.30	0.33%
SSE Composite Index	4,126.09	12.67	-0.31%